©Pixabay

Following our 2021 Wild Card programme, EIT Health has chosen two innovator teams, PeriVision from Switzerland, and INVENTION from Sweden, to receive further support over the next two years.

It will provide the newly formed teams with expert mentoring and coaching, and access to its vast network across Europe. The teams will also receive funding of up to EUR 1.5 million each, writes the European Institute of Innovation and Technology in a press release.

Eye care is an underinvested area

Eye and vision care is both an under-innovated and underinvested area of healthcare. The 2017 Global Burden of Disease Study ranked vision impairment, including blindness, as the third leading cause of years lived with disability. Globally, at least 2.2 billion people around the world have a vision impairment, from which, according to the World Health Organization, almost 50% could be prevented or cured.

Now in its fourth year, the Wild Card programme is part of our open innovation offering, which provides the opportunity for teams and individuals including innovators, medical professionals, and entrepreneurs from all walks of life to come together and solve pressing health challenges. Wild Card builds game-changing life science companies to break new ground in health by challenging the status quo in areas of high unmet need.

Subscribe to our Newsletter!

Your weekly innovation overview Every sunday the best articles of the week in your inbox.

    Network of talents

    Beginning with challenges that we set, the annual Wild Card programme invites talented innovators from across Europe to respond with their ideas. Successful applicants start their journey with a deep dive; putting them through their paces on everything from team formation, critical thinking, business model validation and pitching. Finally, participants pitch their solution to a panel of industry leaders to secure funding to incorporate their company and bring their solution to market.

    Jan-Philipp Beck, CEO, EIT Health: “We’re proud to announce our support for PeriVision and INVENTION, which marks our commitment to improving innovation in the field of eye and vision care. As well as EUR 3 million, we’re providing access to our cross-border, cross-discipline, expertise, and network so that we can innovate together. We hope to rapidly bring new safe and effective technologies to Europeans living with debilitating eye and vision conditions.”

    About the teams selected

    PeriVision, a team of six, from Switzerland will focus on developing a novel artificial intelligence device that will allow for faster diagnosis of glaucoma.

    Patrick Kessel CEO & Cofounder of PeriVision: “Glaucoma is the number one cause of irreversible blindness worldwide, and PeriVision wants to reimagine the way we detect and monitor this condition. We provide private practices and hospitals with a portable and AI-based fast visual field-testing device to optimise workflows and better manage glaucoma. The Wild Card programme helped us tremendously to understand who benefits most from our solution and how we build a sustainable business. The mentors made us look at the problem from a patient, clinician, payor, and investor viewpoint. We are now looking forward to finalising our solution and helping patients and clinicians worldwide.”

    INVENTION, a team of three from Sweden, will develop a natural therapeutic contact lens for the treatment of eye conditions such as myopia and dry eye.

    Mehrdad Rafat, Cofounder of INVENTION: “Globally, more than 2.6 billion people have poor distance vision (myopia) and 1.1 billion suffer from dry eye according to recent WHO reports. Despite the technological advances for treating these conditions separately, millions still suffer from both conditions and are underserved as the existing treatment options are suboptimal. We are developing a Natural Contact Lens made from the same material as the human eye that can help manage myopia in dry eye patients. The EIT Health Wild Card programme helped us better understand the need and examine our assumptions towards developing a solution for addressing a major unmet need in eye and vision care.”

    2022 Wild Card challenges announced

    Following the announcement of the 2021 selected teams, we have launched the focus of our Wild Card challenges for 2022: early detection of cancer and mental health. Topics which were selected in consultation with medical, corporate, and financial experts. Urgent action is needed to address the impact of COVID-19 on cancer and mental health, which were both exacerbated by the pandemic.

    Modelling in several European countries predicts thousands of excess cancer deaths due to the disruption in diagnosis and care. Currently, 52% of people with cancer do not survive, however survival rates are generally higher when the disease is diagnosed and treated early. The Wild Card 2022 cancer challenge has been set to contribute towards innovation that can help to improve the detection of cancer earlier, when it can be more easily and successfully treated.

    The COVID-19 pandemic has also had a considerable impact on the mental health of citizens, with a rise in the reporting of many mental health conditions. One in four people will be affected by a mental health or neurological condition in their lifetime, and around 450 million people are already suffering. The scale of the problem places such conditions among the leading causes of ill-health and disability worldwide. The Wild Card mental health challenge aims to find solutions that can facilitate access to care as well as improve the overall outcomes of those affected.

    Also interesting: New heart valves and blood vessels made from your own tissue

    Selected for you!

    Innovation Origins is the European platform for innovation news. In addition to the many reports from our own editors in 15 European countries, we select the most important press releases from reliable sources. This way you can stay up to date on what is happening in the world of innovation. Are you or do you know an organization that should not be missing from our list of selected sources? Then report to our editorial team.

    Doneer

    Personal Info